Trv Gp Vi LLC Invests $600,000 in Tango Therapeutics, Inc. (NASDAQ:TNGX)

TRV GP VI LLC bought a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 194,174 shares of the company's stock, valued at approximately $600,000. Tango Therapeutics makes up approximately 0.5% of TRV GP VI LLC's portfolio, making the stock its 4th biggest holding. TRV GP VI LLC owned approximately 0.18% of Tango Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Tango Therapeutics during the fourth quarter worth approximately $33,000. Teacher Retirement System of Texas raised its holdings in shares of Tango Therapeutics by 35.8% in the 4th quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company's stock valued at $45,000 after purchasing an additional 3,831 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of Tango Therapeutics during the 4th quarter worth $45,000. Renaissance Technologies LLC acquired a new position in shares of Tango Therapeutics during the fourth quarter worth $66,000. Finally, Wells Fargo & Company MN increased its holdings in Tango Therapeutics by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 22,292 shares of the company's stock valued at $69,000 after buying an additional 7,599 shares during the last quarter. Hedge funds and other institutional investors own 78.99% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and issued a $13.00 price objective on shares of Tango Therapeutics in a report on Monday, April 14th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, Tango Therapeutics has an average rating of "Buy" and an average target price of $12.33.

Insider Activity at Tango Therapeutics

In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of Tango Therapeutics stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $29,236.22. Following the transaction, the chief executive officer now directly owns 1,631,264 shares in the company, valued at approximately $4,877,479.36. The trade was a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 24,268 shares of company stock worth $72,561 in the last 90 days. 6.30% of the stock is owned by insiders.

Tango Therapeutics Stock Performance

Shares of TNGX stock traded down $0.01 during mid-day trading on Friday, hitting $1.46. 304,271 shares of the stock were exchanged, compared to its average volume of 1,073,089. Tango Therapeutics, Inc. has a 12-month low of $1.11 and a 12-month high of $12.02. The stock has a market capitalization of $157.30 million, a price-to-earnings ratio of -1.23 and a beta of 1.03. The stock's fifty day simple moving average is $1.71 and its two-hundred day simple moving average is $3.14.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The firm had revenue of $4.12 million during the quarter, compared to analysts' expectations of $7.84 million. Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. On average, research analysts expect that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

Tango Therapeutics Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.